US FDA slaps Import Alert 66-40 on Dabur's Silvassa drug unit over data integrity lapses

Dabur India disclosed a US FDA Import Alert 66-40 covering certain drug products from part of its Silvassa plant, citing data integrity issues. The company says the hit is immaterial — tied to low-revenue private-label exports — and domestic products are unaffected. Shares slipped 1.32% to ₹422.20.

— Source publishedThu, 11 Jun, 2026, 21:10 IST·First seen Thu, 11 Jun, 2026, 21:17 IST·Source CNBC-TV18 · Companies

What happened

Dabur India · US FDA issued Import Alert 66-40 on drugs from part of Dabur's Silvassa plant over data integrity lapses. Dabur says impact is immaterial, tied to

Key facts

  • ₹422.20
  • 1.32%
  • Import Alert 66-40
  • June 10, 2026

Why this matters

FDA Import Alert 66-40 is a reputational scar that could complicate any future US partnership or licensing discussions, so prioritize remediation transparency to preserve optionality on the export pipeline.